Genetic Testing for Familial Hypercholesterolemia in a Finnish Cohort of Patients with Premature Coronary Artery Disease and Elevated LDL-C Levels

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Aug 12

PMID 39131706

Authors

Antti Jokiniitty

Markku Eskola

Saara Metso

Martin Bogsrud

Heini Huhtala

Tanja Saarela

Affiliations

Soon will be listed here.

Abstract

Background: Based on Finnish -founder variations, the prevalence of familial hypercholesterolemia (FH) in Finland is estimated to be at least 1:600. Patients with FH have increased risk of premature coronary artery disease (CAD) and thus the prevalence of FH is expected to be higher in this subgroup.

Objective: To assess the prevalence of monogenic FH in a Finnish cohort of patients with premature CAD and elevated low-density lipoprotein cholesterol (LDL-C) levels.

Methods: Among 28,295 patients undergoing angiography at Heart Hospital at Tampere University Hospital between 2007 and 2017, we identified 162 patients diagnosed with premature CAD (men aged <55 years and women aged <60 years) and history of high LDL-C (≥5 mmol/L) levels without secondary causes of hypercholesterolemia. Clinical probability of FH was estimated, and genetic testing of FH was carried out in 80 patients with informed consent.

Results: Of the 80 patients with premature CAD and history of high LDL-C levels, 70% were men; the age at diagnosis of CAD for male and female patients was 48 and 53 years, respectively. In total, 58 (73%) patients had probable ( = 54) or definite ( = 4) FH based on Dutch Lipid Clinic Network criteria. A pathogenic variant of FH was found in five (6%) patients. Prevalence of the genetically verified FH was 1:16. The FH variant was found in 75% of patients with definite FH.

Conclusions: The prevalence of genetically verified FH was 1:16 among patients with premature CAD and elevated LDL-C level, which is 38 times higher than the estimated prevalence of 1:600 in the general Finnish population.

References

Hu P, Dharmayat K, Stevens C, Sharabiani M, Jones R, Watts G . Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020; 141(22):1742-1759. DOI: 10.1161/CIRCULATIONAHA.119.044795. View

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991; 303(6807):893-6. PMC: 1671226. DOI: 10.1136/bmj.303.6807.893. View

Jokiniitty A, Eskola M, Saarela T, Huhtala H, Metso S . Role of an automated screening tool for familial hypercholesterolemia in patients with premature coronary artery disease. Atheroscler Plus. 2023; 48:1-7. PMC: 9833226. DOI: 10.1016/j.athplu.2022.01.001. View

Singh A, Gupta A, Collins B, Qamar A, Monda K, Biery D . Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2019; 73(19):2439-2450. DOI: 10.1016/j.jacc.2019.02.059. View

Sturm A, Knowles J, Gidding S, Ahmad Z, Ahmed C, Ballantyne C . Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018; 72(6):662-680. DOI: 10.1016/j.jacc.2018.05.044. View

Louter L, Defesche J, Roeters van Lennep J . Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017; 30:77-85. DOI: 10.1016/j.atherosclerosissup.2017.05.019. View

Futema M, Whittall R, Kiley A, Steel L, Cooper J, Badmus E . Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis. 2013; 229(1):161-8. PMC: 3701838. DOI: 10.1016/j.atherosclerosis.2013.04.011. View

Jenkins N, Lawton J, Douglas M, Walker S, Finnie R, Porteous M . How do index patients participating in genetic screening programmes for familial hypercholesterolemia (FH) interpret their DNA results? A UK-based qualitative interview study. Patient Educ Couns. 2011; 90(3):372-7. DOI: 10.1016/j.pec.2011.09.002. View

10.

di Taranto M, Giacobbe C, Fortunato G . Familial hypercholesterolemia: A complex genetic disease with variable phenotypes. Eur J Med Genet. 2019; 63(4):103831. DOI: 10.1016/j.ejmg.2019.103831. View

11.

Beheshti S, Madsen C, Varbo A, Nordestgaard B . Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol. 2020; 75(20):2553-2566. DOI: 10.1016/j.jacc.2020.03.057. View

12.

Leren T . Cascade genetic screening for familial hypercholesterolemia. Clin Genet. 2004; 66(6):483-7. DOI: 10.1111/j.1399-0004.2004.00320.x. View

13.

Awan Z, Choi H, Stitziel N, Ruel I, Bamimore M, Husa R . APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 2013; 231(2):218-22. DOI: 10.1016/j.atherosclerosis.2013.09.007. View

14.

Huijgen R, Kindt I, Fouchier S, Defesche J, Hutten B, Kastelein J . Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat. 2010; 31(6):752-60. DOI: 10.1002/humu.21258. View

15.

Tokgozoglu L, Kayikcioglu M . Familial Hypercholesterolemia: Global Burden and Approaches. Curr Cardiol Rep. 2021; 23(10):151. DOI: 10.1007/s11886-021-01565-5. View

16.

Jahn B, Santamaria J, Dieplinger H, Binder C, Ebenbichler C, Scholl-Burgi S . Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions. Atherosclerosis. 2022; 355:15-29. DOI: 10.1016/j.atherosclerosis.2022.06.1011. View

17.

Vuorio A, Aalto-Setala K, Koivisto U, Turtola H, Nissen H, Kovanen P . Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group. Ann Med. 2001; 33(6):410-21. DOI: 10.3109/07853890108995954. View

18.

Leren T, Bogsrud M . The importance of cascade genetic screening for diagnosing autosomal dominant hypercholesterolemia: Results from twenty years of a national screening program in Norway. J Clin Lipidol. 2021; 15(5):674-681. DOI: 10.1016/j.jacl.2021.08.007. View

19.

Defesche J, Lansberg P, Umans-Eckenhausen M, Kastelein J . Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med. 2004; 4(1):59-65. DOI: 10.1055/s-2004-822987. View

20.

Leren T, Bogsrud M . Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020. Atherosclerosis. 2021; 322:61-66. DOI: 10.1016/j.atherosclerosis.2021.02.022. View